Complement factor B (CFB), a key enzyme in innate immunity’s complement system, safeguards against microbial threats and has emerged as a crucial biomarker in clinical settings. Vital for the alternative complement pathway’s activation, CFB’s regulation is critical, particularly for protecting against encapsulated bacterial infections. Clinically, its deficiency links to increased susceptibility to infections such as; pneumococcal and meningococcal infections. Moreover, CFB’s diagnostic potential in pancreatic cancer is noteworthy; when combined with CA19-9 in the ComB-CAN panel, it significantly enhances early detection accuracy. Additionally, CFB may contribute to tumor growth by activating the PI3K-AKT pathway, making it an important focus for cancer screening and research.
This product is manufactured in Netherlands by Hycult Biotech.
| Size | 1 x 96 Well |
| Sensitivity | 7.8 ng/mL |
| Dynamic Range | 7.8 – 500 ng/mL |
| Incubation Time | 3 hours 30 minutes |
| Sample Type | Serum, Plasma |
| Immunogen | |
| Source Species | |
| Specificity | |
| Expression System | |
| Clone | |
| Group | |
| Alpha Chain | |
| Beta Chain | |
| Peptide | |
| Peptide Source | |
| Format | |
| Buffer | |
| Concentration | |
| Storage | 2-8°C |
| Alternative Names | CFB |
| Instructions For Use | https://eaglebio.com/wp-content/uploads/2025/03/HK367_Complement_Factor_B_ELISA_Kit_Package_Insert.pdf |
| MSDS | https://eaglebio.com/wp-content/uploads/2025/03/HK367_Complement_Factor_B_ELISA_Kit_SDS.pdf |